On 27 January, Corium, a biopharmaceutical company focused on the development, manufacture and commercialisation of specialty transdermal products, announced that the Food and Drug Administration (FDA) has accepted for filing the new drug application for its investigational donepezil transdermal system Adlarity for the treatment of Alzheimer’s disease (AD).
Adlarity has been designed as a donepezil transdermal patch that would be applied to the skin once weekly. Donepezil is the most commonly prescribed medication to treat the symptoms caused by AD. Currently, donepezil is only available in tablets administered once daily and the most common side effects are gastrointestinal. By delivering donepezil through the skin, the company reported that Adlarity has the potential to reduce gastrointestinal side effects. The FDA’s decision is expected by 30 July.
